These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36507738)

  • 1. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.
    Holze F; Becker AM; Kolaczynska KE; Duthaler U; Liechti ME
    Clin Pharmacol Ther; 2023 Apr; 113(4):822-831. PubMed ID: 36507738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
    Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR
    Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
    Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
    Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants.
    Holze F; Erne L; Duthaler U; Liechti ME
    Br J Clin Pharmacol; 2024 Jan; 90(1):200-208. PubMed ID: 37596682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin.
    Dahmane E; Hutson PR; Gobburu JVS
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):78-85. PubMed ID: 32250059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
    Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME
    Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.
    Dolder PC; Schmid Y; Haschke M; Rentsch KM; Liechti ME
    Int J Neuropsychopharmacol; 2015 Jun; 19(1):. PubMed ID: 26108222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
    Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
    Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
    Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
    Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
    Kanodia J; Lo A; Baldwin RM; Colley K; Zhou K; Bourdet DL
    Clin Transl Sci; 2020 Nov; 13(6):1307-1315. PubMed ID: 32506827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mifepristone after low oral doses.
    Kekkonen R; Heikinheimo O; Mandelin E; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):229-34. PubMed ID: 8922876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
    Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man.
    Hasler F; Bourquin D; Brenneisen R; Vollenweider FX
    J Pharm Biomed Anal; 2002 Sep; 30(2):331-9. PubMed ID: 12191719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
    Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.